Companion Diagnostics: an absolute necessity for targeted therapies

A substitution of a solid tumor biopsy could be a reality. A child can be sequenced at birth so that it can help lead a healthier life. For each expression of the disease, genetic testing plays a crucial role in more accurate testing with better biomarkers approaching the actual genetic material. The promise of personalized medicine could only be through better diagnoses for the development of safer and more effective therapies.

Diagnostics

The companion diagnosis is tests or tests that are used to obtain the genetic and genomic characteristics of the patients and to help doctors and physicians to make better decisions for the treatment of a particular indication. The US Food and Drug Administration defines it as a medical device that identifies a condition for a therapeutic or specific product. Helps provide the most probable and successful therapeutic intervention in obtaining information through patient diagnosis. Many pharmaceutical and biotechnology companies have focused on cost regulation by developing accompanying diagnoses and targeted therapies. To this end, partnerships with diagnostic companies have made significant progress in the development and production of more targeted and effective diagnoses.

How have companies seen opportunities in developing Companion Diagnostics?

The first diagnostic Companion was launched in the 1980s. Its future success depends largely on the sequencing and development of personalized medicine. In 2014, Illumina introduced a sequencing system, X HiSeq Ten One, which reduced the cost of sequencing the human genome into $ 1000 US and was accepted by many families. The system could transcribe nearly 18,000 human genomes in a year. Accompanying diagnoses are mainly used in oncology to analyze tumor samples from a large population. Other indications, such as the treatment of cystic fibrosis, are also highlighted.

The funding environment for diagnostic and research companies is also a key factor. Recently, Qiagen has worked with Centogene to increase the clinical prediction of rare diseases. Inotrem collaborated with Roche Diagnostics to develop an accompanying diagnostic test for septic shock. Although there were many collaborations, the success rate was low. For example, gefitinib, marketed by AstraZeneca, was a disappointing result (the drug does not work in 90% of patients and has produced results, and since then several new drugs have been introduced.The latest FDA diagnostic test approvals are FoundationOne CDx from Foundation Medicine, a genomic profiling test for all solid tumors.

Can Companion Diagnostics succeed in the near future?

A market research firm’s report estimated the CAGR of 35% for the global partner diagnostics market and predicts that the market will be worth approximately $ 26 billion in 2022. Because of the increasing demand for personalized drugs and awareness of the public, the industry has grown considerably. The growing number of cancer cases worldwide has also been an important factor in this market. As companies strengthen their collaboration for better biomarkers and diagnostics, there are great opportunities for applications in non-tumor indications, such as cardiovascular, neurological and other diseases.

Some of the biggest obstacles to this market are the high costs associated with the development of therapeutic products and diagnostic tests. Given the high risk of failure in clinical trials, many organizations prefer collaborations to minimize their failure rate. Repayment problems in several countries are also hindering the growth of this market.

Leave a Reply

Your email address will not be published. Required fields are marked *